Live and let die: asymmetric dimethylarginine and septic shock

被引:0
作者
Rainer H Böger
机构
[1] University Hospital Hamburg-Eppendorf,Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology
来源
Critical Care | / 10卷
关键词
Nitric Oxide; Septic Shock; Sequential Organ Failure Assessment; Sequential Organ Failure Assessment Score; ADMA Level;
D O I
暂无
中图分类号
学科分类号
摘要
Nitric oxide (NO) is an important mediator of host defence and of vascular tone. In septic shock, upregulation of inducible NO synthase leads to the production of vast amounts of NO, which contribute to pathogen elimination but also to inappropriate vasodilation and to loss of vascular resistance. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthases shown to contribute to the regulation of vascular tone. ADMA was recently identified as a marker of organ dysfunction and mortality in intensive care patients and as a novel cardiovascular risk factor. In the present issue of Critical Care, a study by O'Dwyer and colleagues identifies ADMA as a potential regulator of NO production in septic shock. Being an inhibitor of NO production, ADMA may at least partly counteract pathological hypotension, but at the same time may impair the NO-dependent host defence. A mechanism is proposed by which the interplay between ADMA and inducible NO synthase activity is mediated. ADMA levels should be determined in future studies evaluating the regulation of NO in the intensive care setting.
引用
收藏
相关论文
共 50 条
  • [21] Effect of asymmetric dimethylarginine on osteoblastic differentiation
    Xiao, ZS
    Quarles, LD
    Chen, QQ
    Yu, YH
    Qu, XP
    Jiang, CH
    Deng, HW
    Li, YJ
    Zhou, HH
    KIDNEY INTERNATIONAL, 2001, 60 (05) : 1699 - 1704
  • [22] Asymmetric dimethylarginine level in hyperglycemic gestation
    Sertkaya, Ayse Cikim
    Kafkasli, Ayse
    Turkcuoglu, Ilgin
    Karabulut, Aysun Bay
    ENDOCRINE, 2011, 40 (02) : 237 - 242
  • [23] Asymmetric dimethylarginine in children with homocystinuria or phenylketonuria
    Nele Kanzelmeyer
    Dimitrios Tsikas
    Kristine Chobanyan-Jürgens
    Bibiana Beckmann
    Bernhard Vaske
    Sabine Illsinger
    Anibh M. Das
    Thomas Lücke
    Amino Acids, 2012, 42 : 1765 - 1772
  • [24] The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients
    Richir, M. C.
    Ellger, B.
    Teerlink, T.
    Siroen, M. P. C.
    Visser, M.
    Spreeuwenberg, M.
    Girbes, A. R. J.
    van der Hoven, B.
    van den Berghe, G.
    Wilhelm, A. J.
    de Vries, Th. P. G. M.
    van Leeuwen, P. A. M.
    PHARMACOLOGICAL RESEARCH, 2009, 60 (06) : 519 - 524
  • [25] Relationship of asymmetric dimethylarginine to haemodialysis hypotension
    Bergamini, S
    Vandelli, L
    Bellei, E
    Rota, C
    Manfredini, P
    Tomasi, A
    Albertazzi, A
    Iannone, A
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2004, 11 (03): : 273 - 278
  • [26] Association of asymmetric dimethylarginine and endothelial dysfunction
    Böger, RH
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (11) : 1467 - 1472
  • [27] Asymmetric dimethylarginine: predictor of cardiovascular diseases?
    Nemeth Balazs
    Kustan Peter
    Nemeth Adam
    Lenkey Zsofia
    Cziraki Attila
    Kiss Istvan
    Sulyok Endre
    Ajtay Zeno
    ORVOSI HETILAP, 2016, 157 (13) : 483 - 487
  • [28] Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
    Ueda, Seiji
    Yamagishi, Sho-ichi
    Yokoro, Miyuki
    Okuda, Seiya
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (14) : 2448 - 2455
  • [29] Septic shock
    Baxter, F
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1997, 44 (01): : 59 - 72
  • [30] Asymmetric dimethylarginine as cardiovascular risk factor
    Galan, Amparo
    Formiguera, Xavier
    Rey-Joly, Celestino
    MEDICINA CLINICA, 2008, 131 (07): : 271 - 275